Application are invited for Store Keeper (Drugs), Pharmacist Grade-II in AIIMS | 13 Posts

Applications are invited in the prescribed form through online mode for filling of various Group A (Non-Faculty), Group B and Group C posts at the AIIMS, New Delhi as under:

Post: Store Keeper (Drugs), Pharmacist Grade-II

An autonomous body under the AYUSH department of Union Health Ministry is planning to tieup with top homeopathy research organisations with an aim of boosting the healthcare industry. The Central Council for Research in Homeopathy (CCRH), the autonomous body under AYUSH, has called for further research to promote this system of medicine, said Dr R K Manchanda, Director General of CCRH.

India and Canada will partner in health innovations in India focussing on maternal, newborn and child health and Visceral Leishmaniasis elimination and will make an invest of US dollar 2.5 million. The Department of Biotechnology (DBT) and Grand Challenges Canada (GCC), funded by the Government of Canada, will work to eliminate Visceral Leishmaniasis (VL, Kala Azar) in Bihar.

Require Therapy Executives (10 Opening) in Medispan

Medispan Pvt Ltd is a division of Shriram Group based Chennai, is a part of Rs 65000 cr Group having, Diversified Business

Post: Therapy Executives

Online application are invited for Junior Research Fellow in NIRRH

National Institute for Research in Reproductive Health (NIRRH), formerly known as Institute for Research in Reproduction is a premier research institute of the Indian Council of Medical Research (ICMR). It is situated in the vicinity of a number of hospitals and research institutes in central Mumbai. Since its inception in 1970, it has been making vigorous efforts to improve the reproductive health of people through research, education and health care services.

Applications are invited online on or before 05-06-2015 for the following vacancies, purely on temporary basis, in the following ad-hoc research project.

Post:  Junior  Research Fellow

Vacancy as Zonal Manager - Oncology in Roche

At Roche, 80,000 people across 150 countries are pushing back the frontiers of healthcare. Working together, we’ve become one of the world’s leading research-focused healthcare groups. Our success is built on innovation, curiosity and diversity.
Roche Diagnostics India, with a sales turnover of INR 150 crores, nurtures an open, flexible and challenging work environment, which allows for rapid career progression. Favored by its geographic location in the heart of Europe, the Basel area is one of the most dynamic economic regions in Switzerland — a great place to live and work.

Post: Zonal Manager - Oncology (West)

FORMULATION AND PRODUCT DEVLOPMENT OF PRESSURISED METERED DOSE INHALER: AN OVERVIEW

ABOUT AUTHORS:
*S R Thorat1, S M Meshram2
1Lupin Research Park, Hinjewadi, Pune, Maharashtra
2TATA Consultancy Services, Hinjewadi, Pune, Maharashtra
santoshthorat345@gmail.com
{ DOWNLOAD AS PDF }

ABSTRACT
Pressurized metered dose inhalers (MDIs) are widely used dosage form for treatment of respiratory diseases, such as asthma and chronic obstructive pulmonary disease. The metered dose inhaler (MDI) contains the active pharmaceutical ingredient dispersed or solubilised in a high vapour pressure propellant and metered accurately in tens to hundreds of micrograms and administered directly to the lungs. The most dominant characteristics of MDI include their portability, convenience of use and quick effect. MDI comprises of drug formulation, propellant, metering valve, actuator, and container. This review contains overview of excipient selection, primary packaging material, propellant selection and formulation development of pMDI. Two of the most commonly used methods for the manufacturings of MDIs are cold filling method and pressure filling method.This review demonstrates different analytical techniques for characterization of pMDI’s like uniformity of delivered dose, water content, spray pattern and plume geometry were discussed. This review also presents in-vitro characterization, pharmacokinetic and pharamcodynamic study of MDI.

Eli Lilly and Sanford-Burnham, a non-profit medical research institute, will develop potential therapeutics using biotechnology approaches in targeting multiple immune checkpoint modulators for the treatment of immunological diseases such as lupus, Sjögren's Syndrome, inflammatory bowel disease and other autoimmune disorders. This high degree of interaction will allow the organizations to flexibly and efficiently advance projects to clinical investigation. The research collaboration will be co-chaired by Thomas F.

AstraZeneca, innovation-driven biopharmaceutical business,  to invest approximately $285 million in a new facility for manufacturing of biological medicines in Södertälje, Sweden. Södertälje is currently main Place to AstraZeneca’s largest global tablets and capsules manufacturing facility. Company will combine its expertise in biologics with the well-established culture of operational excellence that exists within the Sweden operations unit.
The new plant will be focused on filling and packaging of protein therapeutics.